ReviewCancer drug resistance (Alhambra, Calif.)2022

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them.

Danilo Rocco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.